Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Exclusion Criteria

• •Multi-organ transplant recipients or prior kidney transplant.
• •Recipients of an organ from a non-heart beating donor.
• •Recipient of an organ from an HLA identical living related donor.
• •ABO incompatible or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant
• •Recipients of kidneys from donors who are older than 65 years.
• •Recipients of kidneys from donors with terminal serum creatinine \> 2 mg/dL.
• •Patients at high immunological risk for rejection
• •Patient who is anti-HIV positive, HBsAg-positive or anti-HCV positive (without proof of sustained viral response (SVR) after anti-HCV treatment).
• •Recipient of a kidney from a donor who tests positive for HIV, HBsAg/HBc positive or HCV.
• •A negative Epstein Barr virus (EBV) test.
• •Evidence of advanced liver disease (Child-Pugh C), or any sign of liver decompensation.
• •Patient with severe systemic infections, current or within the two weeks prior to randomization.
• •History of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases, with the exception of localized excised non-melanomatous skin lesions.